Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2011

01-02-2011 | Review

A window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis

Authors: Luke L Gompels, Ewa M Paleolog

Published in: Arthritis Research & Therapy | Issue 1/2011

Login to get access

Abstract

Novel molecular imaging techniques are at the forefront of both preclinical and clinical imaging strategies. They have significant potential to offer visualisation and quantification of molecular and cellular changes in health and disease. This will help to shed light on pathobiology and underlying disease processes and provide further information about the mechanisms of action of novel therapeutic strategies. This review explores currently available molecular imaging techniques that are available for preclinical studies with a focus on optical imaging techniques and discusses how current and future advances will enable translation into the clinic for patients with arthritis.
Appendix
Available only for authorised users
Literature
1.
van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB: Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol. 1995, 22: 1792-1796.PubMed
2.
Felson DT, Zhang Y: An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998, 41: 1343-1355. 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO;2-9.CrossRefPubMed
3.
Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000, 133: 635-646.CrossRefPubMed
4.
5.
Jones G, Ding C, Scott F, Glisson M, Cicuttini F: Early radiographic osteoarthritis is associated with substantial changes in cartilage volume and tibial bone surface area in both males and females. Osteoarthritis Cartilage. 2004, 12: 169-174. 10.1016/j.joca.2003.08.010.CrossRefPubMed
6.
de Bois MH, Pauwels EK, Breedveld FC: New agents for scintigraphy in rheumatoid arthritis. Eur J Nucl Med. 1995, 22: 1339-1346. 10.1007/BF00801624.CrossRefPubMed
7.
Oyen WJ, Boerman OC, van der Laken CJ, Claessens RA, van der Meer JW, Corstens FH: The uptake mechanisms of inflammation- and infection-localizing agents. Eur J Nucl Med. 1996, 23: 459-465. 10.1007/BF01247377.CrossRefPubMed
8.
Levick JR: Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. 1981, 24: 1550-1560. 10.1002/art.1780241215.CrossRefPubMed
9.
Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, Buijs WC, Bakker H, van der Meer JW, Corstens FH: 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med. 2000, 41: 622-630.PubMed
10.
Kaya M, Tuna H, Fatih Firat M, Tuna F, Seren G, Necmi Yigitbasi O: (99m) Tc-dextran scintigraphy to detect disease activity in patients with rheumatoid arthritis. Nucl Med Commun. 2004, 25: 597-601. 10.1097/01.mnm.0000126632.32413.2e.CrossRefPubMed
11.
Arzu Gencoglu E, Aras G, Kucuk O, Atay G, Tutak I, Ataman S, Soylu A, Ibis E: Comparison of Tc-99 m HIG and three-phase Tc-99 m MDP bone scintigraphy for evaluating the efficacy of Yttrium-90 silicate radionuclide synovectomy. Clin Nucl Med. 2003, 28: 277-285. 10.1097/00003072-200304000-00002.PubMed
12.
Adams BK, Al Attia HM, Khadim RA, Al Haider ZY: 99Tc(m) nanocolloid scintigraphy: a reliable way to detect active joint disease in patients with peripheral joint pain. Nucl Med Commun. 2001, 22: 315-318. 10.1097/00006231-200103000-00008.CrossRefPubMed
13.
Desaulniers M, Fuks A, Hawkins D, Lacourciere Y, Rosenthall L: Radiotechnetium polyphosphate joint imaging. J Nucl Med. 1974, 15: 417-423.PubMed
14.
Helfgott S, Rosenthall L, Esdaile J, Tannenbaum H: Generalized skeletal response to 99mtechnetium methylene diphosphonate in rheumatoid arthritis. J Rheumatol. 1982, 9: 939-941.PubMed
15.
Fogelman I: Skeletal uptake of diphosphonate: a review. Eur J Nucl Med. 1980, 5: 473-476.PubMed
16.
Jamar F, Houssiau FA, Devogelaer JP, Chapman PT, Haskard DO, Beaujean V, Beckers C, Manicourt DH, Peters AM: Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology (Oxford). 2002, 41: 53-61. 10.1093/rheumatology/41.1.53.CrossRef
17.
Barrera P, van der Laken CJ, Boerman OC, Oyen WJ, van de Ven MT, van Lent PL, van de Putte LB, Corstens FH: Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2000, 39: 870-874. 10.1093/rheumatology/39.8.870.CrossRef
18.
Barrera P, Oyen WJ, Boerman OC, van Riel PL: Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2003, 62: 825-828. 10.1136/ard.62.9.825.PubMedCentralCrossRefPubMed
19.
Lopes FP, de Azevedo MN, Marchiori E, da Fonseca LM, de Souza SA, Gutfi len B: Use of 99mTc-anti-CD3 scintigraphy in the differential diagnosis of rheumatic diseases. Rheumatology (Oxford). 2010, 49: 933-939. 10.1093/rheumatology/kep471.CrossRef
20.
Notley CA, McCann FE, Inglis JJ, Williams RO: ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis. Arthritis Rheum. 62: 171-178. 10.1002/art.25058.
21.
Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS: Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002, 46: 1947-1955. 10.1002/art.10405.CrossRefPubMed
22.
Wipke BT, Wang Z, Kim J, McCarthy TJ, Allen PM: Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 2002, 3: 366-372. 10.1038/ni775.CrossRefPubMed
23.
Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C: Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol. 2006, 7: 284-292. 10.1038/ni1306.CrossRefPubMed
24.
Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Mottonen T, Nuutila P, Minn H: Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003, 48: 3077-3084. 10.1002/art.11282.CrossRefPubMed
25.
Garrood T, Blades M, Haskard DO, Mather S, Pitzalis C: A novel model for the preclinical imaging of inflamed human synovial vasculature. Rheumatology (Oxford). 2009, 48: 926-931. 10.1093/rheumatology/kep117.CrossRef
26.
McQueen FM, Ostergaard M: Established rheumatoid arthritis - new imaging modalities. Best Pract Res Clin Rheumatol. 2007, 21: 841-856. 10.1016/j.berh.2007.05.001.CrossRefPubMed
27.
D'Agostino MA, Conaghan P, Le Bars M, Baron G, Grassi W, Martin-Mola E, Wakefield R, Brasseur JL, So A, Backhaus M, Malaise M, Burmester G, Schmidely N, Ravaud P, Dougados M, Emery P: EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis. 2005, 64: 1703-1709. 10.1136/ard.2005.037994.PubMedCentralCrossRefPubMed
28.
Eckstein F, Burstein D, Link TM: Quantitative MRI of cartilage and bone: degenerative changes in osteoarthritis. NMR Biomed. 2006, 19: 822-854. 10.1002/nbm.1063.CrossRefPubMed
29.
Williams TG, Holmes AP, Bowes M, Vincent G, Hutchinson CE, Waterton JC, Maciewicz RA, Taylor CJ: Measurement and visualisation of focal cartilage thickness change by MRI in a study of knee osteoarthritis using a novel image analysis tool. Br J Radiol. 2010, 83: 940-948. 10.1259/bjr/68875123.PubMedCentralCrossRefPubMed
30.
Bashir A, Gray ML, Burstein D: Gd-DTPA2- as a measure of cartilage degradation. Magn Reson Med. 1996, 36: 665-673. 10.1002/mrm.1910360504.CrossRefPubMed
31.
Bashir A, Gray ML, Boutin RD, Burstein D: Glycosaminoglycan in articular cartilage: in vivo assessment with delayed Gd(DTPA)(2-)-enhanced MR imaging. Radiology. 1997, 205: 551-558.CrossRefPubMed
32.
Gray ML, Burstein D, Kim YJ, Maroudas A: 2007 Elizabeth Winston Lanier Award Winner. Magnetic resonance imaging of cartilage glycosaminoglycan: basic principles, imaging technique, and clinical applications. J Orthop Res. 2008, 26: 281-291. 10.1002/jor.20482.CrossRefPubMed
33.
Owman H, Tiderius CJ, Neuman P, Nyquist F, Dahlberg LE: Association between findings on delayed gadolinium-enhanced magnetic resonance imaging of cartilage and future knee osteoarthritis. Arthritis Rheum. 2008, 58: 1727-1730. 10.1002/art.23459.CrossRefPubMed
34.
Williams A, Shetty SK, Burstein D, Day CS, McKenzie C: Delayed gadolinium enhanced MRI of cartilage (dGEMRIC) of the first carpometacarpal (1CMC) joint: a feasibility study. Osteoarthritis Cartilage. 2008, 16: 530-532. 10.1016/j.joca.2007.11.002.PubMedCentralCrossRefPubMed
35.
Miese FR, Ostendorf B, Wittsack HJ, Reichelt DC, Mamisch TC, Zilkens C, Lanzman RS, Schneider M, Scherer A: Metacarpophalangeal joints in rheumatoid arthritis: delayed gadolinium-enhanced MR imaging of cartilage - a feasibility study. Radiology. 2010, 257: 441-447. 10.1148/radiol.10100459.CrossRefPubMed
36.
Lewis AR, Nolan MJ, Hodgson RJ, Benjamin M, Ralphs JR, Archer CW, Tyler JA, Hall LD: High resolution magnetic resonance imaging of the proximal interphalangeal joints. Correlation with histology and production of a three-dimensional data set. J Hand Surg Br. 1996, 21: 488-495. 10.1016/S0266-7681(96)80053-2.CrossRefPubMed
37.
Erickson SJ, Kneeland JB, Middleton WD, Jesmanowicz A, Hyde J, Lawson TL, Foley WD: MR imaging of the finger: correlation with normal anatomic sections. AJR Am J Roentgenol. 1989, 152: 1013-1019.CrossRefPubMed
38.
Tan AL, Grainger AJ, Tanner SF, Shelley DM, Pease C, Emery P, McGonagle D: High-resolution magnetic resonance imaging for the assessment of hand osteoarthritis. Arthritis Rheum. 2005, 52: 2355-2365. 10.1002/art.21210.CrossRefPubMed
39.
Tan AL, McGonagle D: Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine. 2010, 77: 206-211. 10.1016/j.jbspin.2009.09.011.CrossRefPubMed
40.
Moore A, Sun PZ, Cory D, Hogemann D, Weissleder R, Lipes MA: MRI of insulitis in autoimmune diabetes. Magn Reson Med. 2002, 47: 751-758. 10.1002/mrm.10110.CrossRefPubMed
41.
Taylor AM, Panting JR, Keegan J, Gatehouse PD, Amin D, Jhooti P, Yang GZ, McGill S, Burman ED, Francis JM, Firmin DN, Pennell DJ: Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging. 1999, 9: 220-227. 10.1002/(SICI)1522-2586(199902)9:2<220::AID-JMRI11>3.0.CO;2-A.CrossRefPubMed
42.
Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK, Morris M, Lucas M: Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J Magn Reson Imaging. 1999, 9: 291-294. 10.1002/(SICI)1522-2586(199902)9:2<291::AID-JMRI21>3.0.CO;2-#.CrossRefPubMed
43.
Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, Edwards AD: Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology. 2006, 241: 469-476. 10.1148/radiol.2412050490.CrossRefPubMed
44.
Stach CM, Bauerle M, Englbrecht M, Kronke G, Engelke K, Manger B, Schett G: Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum. 2010, 62: 330-339.PubMed
45.
46.
Gompels LL, Lim NH, Vincent T, Paleolog EM: In vivo optical imaging in arthritis - an enlightening future?. Rheumatology (Oxford). 2010, 49: 1436-1446. 10.1093/rheumatology/keq012.CrossRef
47.
Kulka JP, Bocking D, Ropes MW, Bauer W: Early joint lesions of rheumatoid arthritis; report of eight cases, with knee biopsies of lesions of less than one year's duration. AMA Arch Pathol. 1955, 59: 129-150.PubMed
48.
Schumacher HR, Kitridou RC: Synovitis of recent onset. A clinicopathologic study during the first month of disease. Arthritis Rheum. 1972, 15: 465-485. 10.1002/art.1780150502.CrossRefPubMed
49.
Hansch A, Frey O, Hilger I, Sauner D, Haas M, Schmidt D, Kurrat C, Gajda M, Malich A, Bräuer R, Kaiser WA: Diagnosis of arthritis using near-infrared fluorochrome Cy5.5. Invest Radiol. 2004, 39: 626-632. 10.1097/01.rli.0000139008.04288.fd.CrossRefPubMed
50.
Fischer T, Gemeinhardt I, Wagner S, Stieglitz DV, Schnorr J, Hermann KG, Ebert B, Petzelt D, Macdonald R, Licha K, Schirner M, Krenn V, Kamradt T, Taupitz M: Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad Radiol. 2006, 13: 4-13. 10.1016/j.acra.2005.07.010.CrossRefPubMed
51.
Andersson SE, Johansson A, Lexmuller K, Ekstrom GM: Physiological characterization of mBSA antigen induced arthritis in the rat. II. Joint blood flow, glucose metabolism, and cell proliferation. J Rheumatol. 1998, 25: 1778-1784.PubMed
52.
Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003, 2: 214-221. 10.1038/nrd1033.CrossRefPubMed
53.
Palframan R, Airey M, Moore A, Vugler A, Nesbitt A: Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009, 348: 36-41. 10.1016/j.jim.2009.06.009.CrossRefPubMed
54.
Patel AM, Moreland LW: Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol. 2010, 6: 855-866. 10.1586/eci.10.69.PubMedCentralCrossRefPubMed
55.
Hansch A, Frey O, Sauner D, Hilger I, Haas M, Malich A, Brauer R, Kaiser WA: In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum. 2004, 50: 961-967. 10.1002/art.20112.CrossRefPubMed
56.
Chen WT, Mahmood U, Weissleder R, Tung CH: Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther. 2005, 7: R310-317. 10.1186/ar1483.PubMedCentralCrossRefPubMed
57.
Simon GH, Daldrup-Link HE, Kau J, Metz S, Schlegel J, Piontek G, Saborowski O, Demos S, Duyster J, Pichler BJ: Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. Eur J Nucl Med Mol Imaging. 2006, 33: 998-1006. 10.1007/s00259-006-0081-y.CrossRefPubMed
58.
Gompels LL, Madden L, Lim NH, Inglis JJ, McConnell E, Vincent TL, Haskard DO, Paleolog EM: In vivo fluorescence imaging of E-selectin: Quantitative detection of endothelial activation in arthritis. Arthritis Rheum. 2011, 63: 107-117. 10.1002/art.30082.CrossRefPubMed
59.
Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY: Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA. 2004, 101: 17867-17872. 10.1073/pnas.0408191101.PubMedCentralCrossRefPubMed
60.
Lang A, Horler D, Baici A: The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol. 2000, 27: 1970-1979.PubMed
61.
Chang CH, Tang Y, Bronson R, Tung CH: Early diagnosis of osteoarthritis using cathepsin B sensitive near-infrared fluorescent probes. Osteoarthritis Cartilage. 2004, 12: 239-244. 10.1016/j.joca.2003.11.005.CrossRefPubMed
62.
Bhaumik S, Gambhir SS: Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA. 2002, 99: 377-382. 10.1073/pnas.012611099.PubMedCentralCrossRefPubMed
63.
Weissleder R, Tung CH, Mahmood U, Bogdanov A: In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999, 17: 375-378. 10.1038/7933.CrossRefPubMed
64.
Chen J, Tung CH, Mahmood U, Ntziachristos V, Gyurko R, Fishman MC, Huang PL, Weissleder R: In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002, 105: 2766-2771. 10.1161/01.CIR.0000017860.20619.23.CrossRefPubMed
65.
Wunder A, Tung CH, Muller-Ladner U, Weissleder R, Mahmood U: In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum. 2004, 50: 2459-2465. 10.1002/art.20379.CrossRefPubMed
66.
Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, Hepperle M, Lane JH, Harriman G, Xu Y, Ocain T, Weissleder R, Mahmood U, Healy AM, Jaffee B: Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum. 2007, 56: 117-128. 10.1002/art.22303.CrossRefPubMed
67.
Wilson T, Hastings JW: Bioluminescence. Annu Rev Cell Dev Biol. 1998, 14: 197-230. 10.1146/annurev.cellbio.14.1.197.CrossRefPubMed
68.
Iris B, Zilberman Y, Zeira E, Galun E, Honigman A, Turgeman G, Clemens T, Gazit Z, Gazit D: Molecular imaging of the skeleton: quantitative real-time bioluminescence monitoring gene expression in bone repair and development. J Bone Miner Res. 2003, 18: 570-578. 10.1359/jbmr.2003.18.3.570.CrossRefPubMed
69.
Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-kappa B activity. J Immunol. 2002, 168: 1441-1446.CrossRefPubMed
70.
Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG: Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. J Clin Invest. 2001, 107: 1293-1301. 10.1172/JCI12037.PubMedCentralCrossRefPubMed
71.
Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ: Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging. 2009, 36 (Suppl 1): S56-68. 10.1007/s00259-009-1078-0.CrossRefPubMed
72.
Linke R, Kuwert T, Uder M, Forst R, Wuest W: Skeletal SPECT/CT of the peripheral extremities. AJR Am J Roentgenol. 2010, 194: W329-335. 10.2214/AJR.09.3288.CrossRefPubMed
73.
Ntziachristos V, Yodh AG, Schnall M, Chance B: Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci USA. 2000, 97: 2767-2772. 10.1073/pnas.040570597.PubMedCentralCrossRefPubMed
74.
Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY: Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci USA. 2010, 107: 4311-4316. 10.1073/pnas.0910283107.PubMedCentralCrossRefPubMed
75.
Ostendorf B, Scherer A, Wirrwar A, Hoppin JW, Lackas C, Schramm NU, Cohnen M, Mödder U, van den Berg WB, Müller HW, Schneider M, Joosten LA: High-resolution multipinhole single-photon-emission computed tomography in experimental and human arthritis. Arthritis Rheum. 2006, 54: 1096-1104. 10.1002/art.21732.CrossRefPubMed
76.
Ostendorf B, Mattes-Gyorgy K, Reichelt DC, Blondin D, Wirrwar A, Lanzman R, Muller HW, Schneider M, Modder U, Scherer A: Early detection of bony alterations in rheumatoid and erosive arthritis of finger joints with high-resolution single photon emission computed tomography, and differentiation between them. Skeletal Radiol. 2010, 39: 55-61. 10.1007/s00256-009-0761-3.CrossRefPubMed
77.
Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007, 188: 586-592. 10.2214/AJR.06.1094.CrossRefPubMed
78.
Buyukhatipoglu K, Clyne AM: Superparamagnetic iron oxide nanoparticles change endothelial cell morphology and mechanics via reactive oxygen species formation. J Biomed Mater Res A. 2010,
79.
Buyukhatipoglu K, Miller TA, Clyne AM: Flame synthesis and in vitro biocompatibility assessment of superparamagnetic iron oxide nanoparticles: cellular uptake, toxicity and proliferation studies. J Nanosci Nanotechnol. 2009, 9: 6834-6843.CrossRefPubMed
80.
Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, Smolen JS: Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum. 2009, 60: 1242-1249. 10.1002/art.24433.CrossRefPubMed
81.
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005, 52: 1020-1030. 10.1002/art.20982.CrossRefPubMed
82.
Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006, 54: 3119-3125. 10.1002/art.22143.CrossRefPubMed
83.
Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boffers M, Dijkmans BA: Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004, 50: 36-42. 10.1002/art.11481.CrossRefPubMed
84.
Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 2958-2967. 10.1002/art.23945.CrossRefPubMed
85.
Lee L, Buckley C, Blades MC, Panayi G, George AJ, Pitzalis C: Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum. 2002, 46: 2109-2120. 10.1002/art.10464.CrossRefPubMed
86.
Gold L, Polisky B, Uhlenbeck O, Yarus M: Diversity of oligonucleotide functions. Annu Rev Biochem. 1995, 64: 763-797. 10.1146/annurev.bi.64.070195.003555.CrossRefPubMed
87.
Famulok M, Mayer G: Aptamers as tools in molecular biology and immunology. Curr Top Microbiol Immunol. 1999, 243: 123-136.PubMed
88.
Watson SR, Chang YF, O'Connell D, Weigand L, Ringquist S, Parma DH: Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev. 2000, 10: 63-75. 10.1089/oli.1.2000.10.63.CrossRefPubMed
89.
Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N: 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem. 1998, 273: 20556-20567. 10.1074/jbc.273.32.20556.CrossRefPubMed
90.
Csaky K: Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology. 2003, 110: 879-881. 10.1016/S0161-6420(03)00095-2.CrossRefPubMed
91.
Charlton J, Sennello J, Smith D: In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997, 4: 809-816. 10.1016/S1074-5521(97)90114-9.CrossRefPubMed
92.
Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG: Tumor targeting by an aptamer. J Nucl Med. 2006, 47: 668-678.PubMed
93.
Huang YF, Chang HT, Tan W: Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal Chem. 2008, 80: 567-572. 10.1021/ac702322j.CrossRefPubMed
94.
Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS: Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther. 2006, 8: R77-10.1186/ar1944.PubMedCentralCrossRefPubMed
95.
Tsien RY: Constructing and exploiting the fluorescent protein paintbox (Nobel Lecture). Angew Chem Int Ed Engl. 2009, 48: 5612-5626. 10.1002/anie.200901916.CrossRefPubMed
96.
Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA, Tsien RY: Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science. 2009, 324: 804-807. 10.1126/science.1168683.PubMedCentralCrossRefPubMed
97.
Razansky D, Distel M, Vinegoni C, Ma R, Perrimon N, Koster RW, Ntziachristos V: Multispectral opto-acoustic tomography of deep-seated fluorescent proteins in vivo. Nat Photonics. 2009, 3: 412-417. 10.1038/nphoton.2009.98.CrossRef
Metadata
Title
A window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis
Authors
Luke L Gompels
Ewa M Paleolog
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2011
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3197

Other articles of this Issue 1/2011

Arthritis Research & Therapy 1/2011 Go to the issue

Letter

Response to: Comparison of laser Doppler imaging, fingertip lacticemy test, and nailfold capillaroscopy for assessment of digital microcirculation in systemic sclerosis - authors' reply

Research article

Validation of rheumatoid arthritis diagnoses in health care utilization data

Research article

Follistatin-like protein 1 is elevated in systemic autoimmune diseases and correlated with disease activity in patients with rheumatoid arthritis

Editorial

Molecular targets of natural health products in arthritis

Research article

Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus

Review

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits